Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL335 Target Snapshot

Tyrosine-protein phosphatase non-receptor type 1 · SINGLE PROTEIN · Homo sapiens

5,893Compounds
1,137Assays
8Approved Drugs
5,863.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt P18031. Use UniProt P18031 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P18031 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Tyrosine-protein phosphatase non-receptor type 1 as ChEMBL target CHEMBL335, mapped to UniProt P18031. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Tyrosine-protein phosphatase non-receptor type 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL335
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P18031
Tyrosine-protein phosphatase non-receptor type 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Tyrosine-protein phosphatase non-receptor type 1 is the right protein anchor across sources, using UniProt P18031 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelTyrosine-protein phosphatase non-receptor type 1
UniProt AccessionP18031
Component TypeProtein
Sequence Length435 aa

Tyrosine-protein phosphatase non-receptor type 1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Tyrosine-protein phosphatase non-receptor type 1, mapped to UniProt P18031. Sequence length is 435 aa.

Mapped IDP18031
Review nameTyrosine-protein phosphatase non-receptor type 1
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

8
Approved
3
Phase III
13
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC504,802.0
KI992.0
EC501.0
KD68.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL444092 10.0 IC50 0.1 Preclinical
CHEMBL430266 9.52 IC50 0.3 Preclinical
CHEMBL4524071 9.38 IC50 0.42 Preclinical
CHEMBL5619806 9.2 IC50 0.63 Preclinical
CHEMBL244563 9.17 Ki 0.68 Preclinical
CHEMBL505512 9.17 IC50 0.67 Preclinical
CHEMBL5095164 9.16 IC50 0.69 Clinical
CHEMBL184444 9.04 Ki 0.92 Preclinical
CHEMBL5076419 9.0 IC50 1.0 Preclinical
CHEMBL5085615 9.0 IC50 1.0 Preclinical
Distribution

pChEMBL Value Distribution

1109
5.0
769
5.5
502
6.0
298
6.5
183
7.0
97
7.5
39
8.0
29
8.5
11
9.0
1
9.5
pChEMBL
Assay Landscape

Assay Landscape

1,142
Total Assays
3,967
Tested Compounds
4
Assay Types
Binding — 1,127 assays, 3,967 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 783 2,967 5.5
assay format 247 826 5.3
cell-based format 94 143 5.6
tissue-based format 2 3 9.3
organism-based format 1 28 5.2
Functional — 10 assays, 13 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 8 0
assay format 2 13 4.3
ADME — 4 assays, 7 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 3 1 5.7
assay format 1 6 4.5
Toxicity — 1 assays, 19 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 19 6.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine